Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1709-1715

  Ozcan, Muhammet Fuat ^a   Dizdar, Omer ^a   Dincer, Nazmiye ^a   Balci, Serdar ^a   Guler, Gulnur ^a   Gok, Bahri ^a   Pektas, Gokhan ^a   Seker, Mehmet Metin ^b   Aksoy, Sercan ^c   Arslan, Cagatay ^c   Yalcin, Suayib ^c   Balbay, Mevlana Derya ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bladder cancer; Chemotherapy; ERCC1

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE;

ADULT; AGE; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

BLADDER CANCER; CHEMOTHERAPY; ERCC1;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84886288582     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.06.014     Document Type: Article

References (30)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
2. Quek M.L., Stein J.P., Clark P.E., et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 2003, 98:955-961.
3. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Discussion:205-6.
4. Sancar A. Mechanisms of DNA excision repair. Science 1994, 266:1954-1956.
5. Chen S., Zhang J., Wang R., et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression?. A meta-analysis. Lung Cancer 2010, 70:63-70.
6. Dabholkar M., Vionnet J., Bostick-Bruton F., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94:703-708.
7. Park J.S., Jeon E.K., Chun S.H., et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol 2011, 120:275-279.
8. Hoffmann A.C., Wild P., Leicht C., et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12:628-636.
9. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18:522-528.
10. Matsumura N., Nakamura Y., Kohjimoto Y., et al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int 2010, 108:E110-E116.
11. Kim K.H., Do I.G., Kim H.S., et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 2010, 118:941-948.
12. Booth C.M., Siemens D.R., Tannock I., et al. Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. J Clin Oncol 2011, 29.
13. Yacoub A., Park J.S., Qiao L., et al. MAPK dependence of DNA damage repair: Ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol 2001, 77:1067-1078.
14. Schmidt-Ullrich R.K., Valerie K.C., Chan W., et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 1994, 29:813-819.
15. Schneider S., Uchida K., Brabender J., et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005, 200:336-344.
16. Pápay J., Sápi Z., Egri G., et al. Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1. Pathol Oncol Res 2009, 15:445-450.
17. Lin K., Ye D., Xie X. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2008, 18:1007-1012.
18. Smith J.A., Gaikwad A., Ramondetta L.M., et al. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol 2006, 103:518-522.
19. Scheil-Bertram S., Tylus-Schaaf P., du Bois A., et al. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol 2010, 119:325-331.
20. Ozkan M., Akbudak I.H., Deniz K., et al. Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev 2010, 11:181-185.
21. Guix M., Lema L., Lloreta J., et al. Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry. J Clin Oncol 2009, 27(Suppl). Abstract 5025.
22. Kawashima A., Nakayama M., Kakuta Y., et al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 2011, 17:2561-2569.
23. Shariat S.F., Chade D.C., Karakiewicz P.I., et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010, 183:68-75.
24. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008, 112:315-325.
25. Font A., Taron M., Gago J.L., et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011, 22:139-144.
26. Pinho M.B., Costas F., Sellos J., et al. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urol Oncol 2009, 27:382-390.
27. Grossman H.B., Tangen C.M., Cordon-Cardo C., et al. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A southwest oncology group study. Oncol Rep 2006, 16:807-810.
28. Takata R., Katagiri T., Kanehira M., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005, 11:2625-2636.
29. Cooke P.W., James N.D., Ganesan R., et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000, 85:829-835.
30. Kakehi Y., Ozdemir E., Habuchi T., et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 1998, 89:214-220.